Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis.

Chi-Chao Chao Shiou-Ru Tzeng Ming-Chang Chiang Hsueh-Wen HsuehWan-Jen HsiehYuan-Chun ChaoMei-Fang ChengYen-Hung LinMao-Yuan SuChun-Hsiang HuangYi-Shiang WangMing-Fang HsiehPing-Huei TsengSung-Tsang Hsieh

Published in: Annals of clinical and translational neurology (2024)

The binding patterns of both tafamidis and diflunisal to A97S-TTR closely resembled those observed in the wild type. Diflunisal can effectively delay the progression of polyneuropathy and cardiomyopathy with similar efficacy to tafamidis and may become a cost-effective alternative treatment for late-onset ATTRv-PN.

Keyphrases

wild type
late onset
early onset
heart failure
replacement therapy
binding protein
dna binding
smoking cessation